These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22530161)

  • 1. LSVT LOUD and LSVT BIG: Behavioral Treatment Programs for Speech and Body Movement in Parkinson Disease.
    Fox C; Ebersbach G; Ramig L; Sapir S
    Parkinsons Dis; 2012; 2012():391946. PubMed ID: 22530161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lee Silverman Voice Treatment (LSVT)-BIG to improve motor function in people with Parkinson's disease: a systematic review and meta-analysis.
    McDonnell MN; Rischbieth B; Schammer TT; Seaforth C; Shaw AJ; Phillips AC
    Clin Rehabil; 2018 May; 32(5):607-618. PubMed ID: 28980476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
    Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
    J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2022 Jan; 57(1):138-151. PubMed ID: 34767290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of PD Check-In on self-management skills for maintenance of speech after intensive treatment.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2024; 59(4):1628-1646. PubMed ID: 38377119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders.
    Fox CM; Ramig LO; Ciucci MR; Sapir S; McFarland DH; Farley BG
    Semin Speech Lang; 2006 Nov; 27(4):283-99. PubMed ID: 17117354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovative technology for the assisted delivery of intensive voice treatment (LSVT®LOUD) for Parkinson disease.
    Halpern AE; Ramig LO; Matos CE; Petska-Cable JA; Spielman JL; Pogoda JM; Gilley PM; Sapir S; Bennett JK; McFarland DH
    Am J Speech Lang Pathol; 2012 Nov; 21(4):354-67. PubMed ID: 23071195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LSVT-BIG therapy in Parkinson's disease: physiological evidence for proprioceptive recalibration.
    Peterka M; Odorfer T; Schwab M; Volkmann J; Zeller D
    BMC Neurol; 2020 Jul; 20(1):276. PubMed ID: 32652957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of LSVT BIG intervention to address gait, balance, bed mobility, and dexterity in people with Parkinson disease: a case series.
    Janssens J; Malfroid K; Nyffeler T; Bohlhalter S; Vanbellingen T
    Phys Ther; 2014 Jul; 94(7):1014-23. PubMed ID: 24557655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
    Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
    Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative clinical assessment of motor function during and following LSVT-BIG® therapy.
    Flood MW; O'Callaghan BPF; Diamond P; Liegey J; Hughes G; Lowery MM
    J Neuroeng Rehabil; 2020 Jul; 17(1):92. PubMed ID: 32660495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurobehavioral Effects of LSVT
    Li Y; Tan M; Fan H; Wang EQ; Chen L; Li J; Chen X; Liu H
    Front Neurosci; 2021; 15():624801. PubMed ID: 33716652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lee Silverman Voice Treatment to Improve Speech in Parkinson's Disease: A Systemic Review and Meta-Analysis.
    Pu T; Huang M; Kong X; Wang M; Chen X; Feng X; Wei C; Weng X; Xu F
    Parkinsons Dis; 2021; 2021():3366870. PubMed ID: 35070257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive Voice Treatment (Lee Silverman Voice Treatment [LSVT LOUD]) for Children With Down Syndrome: Phase I Outcomes.
    Boliek CA; Halpern A; Hernandez K; Fox CM; Ramig L
    J Speech Lang Hear Res; 2022 Apr; 65(4):1228-1262. PubMed ID: 35230877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Ramig L; Halpern A; Spielman J; Fox C; Freeman K
    Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telerehabilitation for Lee Silverman Voice Treatment (Tele-LSVT)-Loud on voice intensity and voice use in daily living in people with multiple sclerosis: A protocol for a feasibility and pilot randomized controlled study.
    Vitali C; Fusari G; Baldanzi C; Cacciatore DM; Crispiatico V; Carullo A; Rovaris M; Cattaneo D; Baglio F; Isernia S
    Digit Health; 2023; 9():20552076231218150. PubMed ID: 38074343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.